Phase III Kesimpta data show nearly 80% of RMS patients had no evidence of disease activity

27 June 2022

Novartis (NOVN: VX) presented new data at the European Academy of Neurology (EAN) Congress demonstrating treatment with Kesimpta (ofatumumab) significantly increased the odds of achieving no evidence of disease activity (NEDA-3, defined as having no MS relapses, no disability worsening and no MRI activity) versus switching from teriflunomide in people living with relapsing multiple sclerosis (RMS).

The Swiss pharma giant noted that data from the long-term, Phase III ASCLEPIOS I/II trials and the ALITHIOS open-label extension found:

After four years, nearly eight out of 10 of people with RMS treated continuously with Kesimptaachieved NEDA-3 compared with five out of 10 of those who switched to Kesimpta at a later date after initial teriflunomide treatment.
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study.
Kesimpta was associated with significant improvements in cognitive processing speed versus those treated with teriflunomide; these improvements were more pronounced in the subgroup of patients recently diagnosed with RMS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK